Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Esketamine Combined With Transcutaneous Electrical Acupoint Stimulation on Postoperative Recovery Quality After Elective Cesarean Section

29. oktober 2026 oppdatert av: Li Juan, Anhui Provincial Hospital

Effects of Esketamine Combined With Transcutaneous Electrical Acupoint Stimulation on Postoperative Recovery Quality in Parturients Undergoing Cesarean Section: a Prospective Randomized Controlled Trial

This study is a prospective randomized controlled trial aimed at evaluating whether the combination of esketamine and transcutaneous electrical acupoint stimulation (TEAS) can improve the quality of postoperative recovery in women undergoing elective cesarean section. First-time mothers scheduled for surgery will be randomly assigned to one of four groups: a control group (standard care), a TEAS group, an esketamine group, or a combined group (TEAS plus esketamine). TEAS will be applied to specific acupoints before delivery. Esketamine (0.15 mg/kg) will be administered intravenously immediately after the umbilical cord is clamped to minimize fetal exposure. The primary outcome is the overall quality of recovery, assessed using the ObsQoR-11 scale during the first three days after surgery. We will also evaluate pain levels, sleep quality, anxiety and depression, early recovery milestones, inflammatory responses, adverse reactions, and newborn safety. The results may provide an effective multi-modal strategy to enhance recovery for mothers after a cesarean delivery.

Studieoversikt

Detaljert beskrivelse

Background and Rationale:

Cesarean section is one of the most common obstetric surgeries globally. Inadequate postoperative pain management can negatively impact maternal sleep, early ambulation, breastfeeding, and increase the risk of postpartum anxiety and depression. Esketamine, an NMDA receptor antagonist, provides effective analgesia, opioid-sparing effects, and mood regulation. Transcutaneous electrical acupoint stimulation (TEAS) is a non-invasive neuromodulation technique that exerts analgesic effects through the endogenous opioid system and regulates gastrointestinal function. The clinical benefits of esketamine and TEAS are complementary, suggesting a potential synergistic effect in multimodal analgesia and enhanced recovery after surgery (ERAS).

Specific Study Design Rationale:

The acupoints selected in this trial (PC6, HT7, and LI4) are specifically targeted for their effects on pain relief, anxiolysis, and gastrointestinal motility. A disperse-dense frequency (2/10 Hz) is utilized to prevent nerve adaptation and maximize tolerance. Furthermore, to minimize fetal exposure, esketamine will be administered intravenously only after fetal delivery and umbilical cord clamping.

Significance:

This study aims to translate the theoretical synergistic benefits of these two interventions into clinical evidence. The findings will determine whether this combined strategy offers incremental benefits over single interventions in improving the overall quality of recovery for parturients, thereby providing a robust clinical basis for optimizing multimodal analgesic and ERAS protocols.

Studietype

Intervensjonell

Registrering (Antatt)

384

Fase

  • Ikke aktuelt

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 99 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Hunn

Beskrivelse

Inclusion Criteria:

- Age ≥ 18 years. (No upper age limit).

Primiparous women.

American Society of Anesthesiologists (ASA) physical status I or II.

Gestational age between 37 and 42 weeks.

Scheduled for elective cesarean section under epidural anesthesia.

Exclusion Criteria:

- History of allergy or contraindication to esketamine.

Contraindications to neuraxial anesthesia (e.g., coagulopathy).

Severe pregnancy complications (e.g., severe fetal distress, umbilical cord prolapse, placenta previa with massive hemorrhage, placental abruption).

Severe dysfunction of vital organs.

Skin breakdown or infection at the selected acupoint sites.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Placebo komparator: Control Group

Participants receive sham TEAS (device turned off) and an intravenous injection of 10 mL normal saline after umbilical cord clamping.

10 mL of 0.9% normal saline administered intravenously as a placebo immediately after umbilical cord clamping.

The TEAS device is applied to the same acupoints but with the electrical current turned off (the light flashes to blind the participant).

Eksperimentell: TEAS Group

Participants receive active TEAS at PC6, HT7, and LI4 acupoints, and an intravenous injection of 10 mL normal saline after umbilical cord clamping.

10 mL of 0.9% normal saline administered intravenously as a placebo immediately after umbilical cord clamping.

Applied bilaterally at PC6 (Neiguan), HT7 (Shenmen), and LI4 (Hegu) acupoints using a Hwato DZ-III stimulator. Parameters: disperse-dense frequency of 2/10 Hz, intensity adjusted to the maximum tolerable level (6-12 mA).

Eksperimentell: Esketamine Group

Participants receive sham TEAS and an intravenous injection of 0.15 mg/kg esketamine (diluted in 10 mL normal saline) after umbilical cord clamping.

The TEAS device is applied to the same acupoints but with the electrical current turned off (the light flashes to blind the participant).

Administered intravenously at a dose of 0.15 mg/kg (diluted in 10 mL normal saline) immediately after umbilical cord clamping.

Eksperimentell: Combined Group

Participants receive active TEAS and an intravenous injection of 0.15 mg/kg esketamine (diluted in 10 mL normal saline) after umbilical cord clamping.

Applied bilaterally at PC6 (Neiguan), HT7 (Shenmen), and LI4 (Hegu) acupoints using a Hwato DZ-III stimulator. Parameters: disperse-dense frequency of 2/10 Hz, intensity adjusted to the maximum tolerable level (6-12 mA).

Administered intravenously at a dose of 0.15 mg/kg (diluted in 10 mL normal saline) immediately after umbilical cord clamping.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Quality of Postoperative Recovery
Tidsramme: Postoperative days 1, 2, and 3.

Assessed using the ObsQoR-11 (Obstetric Quality of Recovery-11) scale. The score ranges from 0 to 110, with higher scores indicating better quality of recovery.

Postoperative days 1, 2, and 3.

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Postoperative Pain and Sedation
Tidsramme: 12, 24, and 48 hours postoperatively (for VAS and PCA); perioperative period (for sedation).

Visual Analogue Scale (VAS) scores at rest and during movement (0 = no pain, 10 = worst pain); consumption and effective presses of patient-controlled analgesia (PCA); requirement for rescue analgesics (Flurbiprofen axetil); and Ramsay sedation scores.

12, 24, and 48 hours postoperatively (for VAS and PCA); perioperative period (for sedation).
Sleep Quality and Psychological Status
Tidsramme: 1 month preoperatively, postoperative days 1-2, and 1 month postoperatively.

Pittsburgh Sleep Quality Index (PSQI) for preoperative sleep; Leeds Sleep Evaluation Questionnaire (LSEQ) for postoperative sleep; Hospital Anxiety and Depression Scale (HADS); and Edinburgh Postnatal Depression Scale (EPDS).

1 month preoperatively, postoperative days 1-2, and 1 month postoperatively.
Perioperative Hemodynamic Parameters
Tidsramme: Baseline, after block reaches T6-S, skin incision, 1 and 5 minutes after study drug injection, fetal delivery, end of surgery, and 1 and 2 hours postoperatively.

Heart Rate (HR), Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP), and Mean Arterial Pressure (MAP).

Baseline, after block reaches T6-S, skin incision, 1 and 5 minutes after study drug injection, fetal delivery, end of surgery, and 1 and 2 hours postoperatively.
Early Recovery Milestones and Perioperative Data
Tidsramme: From surgery to hospital discharge.

Time to first flatus, first urination, first ambulation, and urinary catheter removal; length of hospital stay; surgical duration; intraoperative blood loss, urine output, and fluid infusion volume.

From surgery to hospital discharge.
Inflammatory Markers
Tidsramme: baseline and on postoperative day 2.

White Blood Cell (WBC) count, Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Monocyte-to-Lymphocyte Ratio (MLR).

baseline and on postoperative day 2.
Maternal Adverse Events and Neonatal Outcomes
Tidsramme: Intraoperative and postoperative days 1-3 (for maternal outcomes); immediately after delivery (for neonatal outcomes).

Incidence of maternal adverse reactions (e.g., nausea, vomiting, dizziness, hallucinations, skin allergies, respiratory depression); neonatal Apgar scores at 1 and 5 minutes; umbilical cord blood gas analysis (pH, Base Excess, lactate); and NICU admission rate.

Intraoperative and postoperative days 1-3 (for maternal outcomes); immediately after delivery (for neonatal outcomes).

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

30. oktober 2026

Primær fullføring (Antatt)

30. oktober 2027

Studiet fullført (Antatt)

30. oktober 2027

Datoer for studieregistrering

Først innsendt

29. oktober 2026

Først innsendt som oppfylte QC-kriteriene

29. oktober 2026

Først lagt ut (Faktiske)

4. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

4. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

29. oktober 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • 2026KY498

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

IPD-planbeskrivelse

Individual participant data will not be shared due to patient privacy and ethical restrictions. The data contains sensitive maternal and neonatal health information, and the informed consent obtained from participants does not permit public data sharing.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere